Abstract:Pathologic cardiac hypertrophy is a common consequence of many cardiovascular diseases, including aortic stenosis. Aortic stenosis is known to increase the pressure load of the left ventricle, causing a compensative response of the cardiac muscle, which progressively will lead to dilation and heart failure. In a cellular level, this corresponds to a considerable increase in the size of cardiomyocytes, named cardiomyocyte hypertrophy, as their proliferation capacity is attenuated upon the first developmental stages. Cardiomyocytes, in order to cope with the increased workload (overload), suffer alterations in their morphology, nuclear content, energy metabolism, intracellular homeostatic mechanisms, contractile activity and cell death mechanisms. Moreover, modifications in the cardiomyocyte niche, involving inflammation, immune infiltration, fibrosis and angiogenesis, contribute to the subsequent events of a pathologic hypertrophic response. Considering the emerging need for a better understanding of the condition and treatment improvement, as the only available treatment option of aortic stenosis consists of surgical interventions at a late stage of the disease, when the cardiac muscle state is irreversible, large animal models have been developed to mimic the human condition, to the greatest extend. Smaller animal models lack physiology and cellular and molecular mechanisms that sufficiently resemblance humans; in vitro techniques yet fail to provide adequate complexity. Animals, such as the ferret ( Mustello purtorius furo ), lapine (rabbit, Oryctolagus cunigulus ), feline (cat, Felis catus ), canine (dog, Canis lupus familiaris ), ovine (sheep, Ovis aries ) and porcine (pig, Sus scrofa ), have contributed to the research by elucidating implicated cellular and molecular mechanisms of the condition. Essential discoveries of each model are reported and discussed briefly in this review. Results of large animal experimentation could further be interpreted aiming to the prevention of the disease progress or, alternatively, to the regression of the implicated pathologic mechanisms to a physiologic state. This review summarizes the important aspects of the pathophysiology of LV hypertrophy and the applied surgical large animal models that better mimic the condition until the present moment.

Large animal models of pressure overload-induced cardiac left ventricular hypertrophy to study remodeling of the human heart with aortic stenosis

Large Mammalian Animal Models of Heart Disease

Large animal models of heart failure with preserved ejection fraction

Small Mammalian Animal Models of Heart Disease.

Large and Small Animal Models of Heart Failure With Reduced Ejection Fraction

Porcine Model of Hypertrophy-Independent Left Ventricular Stiffening via Repetitive Pressure Overload

Congestive heart failure: experimental model

Comparison of the stage-dependent mitochondrial changes in response to pressure overload between the diseased right and left ventricle in the rat

Cardiac structural remodeling in hypertensive cardiomyopathy

Evaluation of large animal models for preclinical studies of heart failure with preserved ejection fraction using clinical score systems

Small and large animal models in cardiac contraction research: advantages and disadvantages

Animal Models of Cardiac Disease and Stem Cell Therapy.

A new technique for producing pure aortic stenosis in animals

Morphological and Functional Characteristics of Animal Models of Myocardial Fibrosis Induced by Pressure Overload

Left Ventricular Response in the Transition from Hypertrophy to Failure Recapitulates Distinct Roles of Akt, Β-Arrestin-2, and CaMKII in Mice with Aortic Regurgitation

Clinical Phenotypes of Heart Failure With Preserved Ejection Fraction to Select Preclinical Animal Models

Left Ventricular Remodeling in Degenerative Aortic Valve Stenosis

Animal Models for Heart Transplantation Focusing on the Pathological Conditions

The transverse aortic constriction heart failure animal model: a systematic review and meta-analysis

Animal models of pulmonary hypertension: Getting to the heart of the problem

Large animal models to study effectiveness of therapy devices in the treatment of heart failure with preserved ejection fraction (HFpEF)